Tropical Journal of Pharmaceutical Research

Original Research Article | OPEN ACCESS

Therapeutic benefit of aripiprazole-olanzapine combination in the treatment of senile Alzheimer disease complicated by mental disorders

Na Zheng , Ning Wang, Ji-Min Jia

Department of Psychiatry, Binzhou People's Hospital, Binzhou 256600, PR China;

For correspondence:- Na Zheng Email: zhengnaii@163.com

Accepted: 24 January 2020 Published: 29 February 2020

Citation: Zheng N, Wang N, Jia J. Therapeutic benefit of aripiprazole-olanzapine combination in the treatment of senile Alzheimer disease complicated by mental disorders. Trop J Pharm Res 2020; 19(2):441-446 doi: 10.4314/tjpr.v19i2.29

© 2020 The authors.
This is an Open Access article that uses a funding model which does not charge readers or their institutions for access and distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0) and the Budapest Open Access Initiative (http://www.budapestopenaccessinitiative.org/read), which permit unrestricted use, distribution, and reproduction in any medium, provided the original work is properly credited..

Abstract

Purpose: To determine the clinical efficacy of aripiprazole-olanzapine combination treatment in elderly Alzheimer’s disease complicated with mental disorders.

Methods: Ninety-two elderly patients with Alzheimer’s disease and mental disorders who were admitted to Binzhou People's Hospital, were enrolled in the study. They were randomized into control and study groups. Control group was treated with olanzapine, while the study group was treated with aripiprazole as an adjuvant therapy in addition to olanzapine. The clinical efficacy, scores on different scales (MMSE, ADAS-cog, CDR, ADL, NPI and CMAI), and incidence of adverse reactions were determined.

Results: The overall degree of response was significantly higher in the study group than in the control group (p < 0.05). There were no significant differences in MMSE, ADAS-cog, CDR, ADL, NPI and CMAI scores between the two groups before treatment (p > 0.05). The MMSE score of the study group was significantly higher than that of the control group, and the scores in the other scales in the study group were significantly lower after treatment (p < 0.05). The study group had significantly lower incidence of adverse reactions than control group (p < 0.05).

Conclusion: Aripiprazole-olanzapine combination has significant therapeutic benefit in the treatment of elderly Alzheimer’s disease patients complicated with mental disorders. It promotes recovery of neurological function, as well as produces a lower incidence of adverse reactions.

Keywords: Aripiprazole, Olanzapine, Alzheimerâ€™s disease, Mental disorders